Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Novolog, NovoLog FlexPen, NovoRapid (Show all)
Generic Name: Insulin Aspart
Insulin aspart is a rapid-acting insulin used for the treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Diabetes Type 1 | 61 | 7 |
|
|
|
||
| Diabetes Type 2 | 45 | 4 |
|
|
|
||
| Other | 9 | 1 |
|
||||
| LOWER BEFORE MEAL BLOODSUGAR | 3 | 0 | |||||
| Diabetes Mellitus | 3 | 0 | |||||
| Elevated blood sugar (hyperglycemia) | 3 | 0 |
See all 137 patients currently taking Insulin Aspart
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Insulin Aspart
| Low blood sugar (hypoglycemia) | 3 | |
|---|---|---|
| Weight gain | 2 | |
| Injection site redness | 1 | |
| Shakiness | 1 | |
| Injection site itching | 1 | |
| hard to control blood sugars | 1 |
Frequently reported dosages based on patients currently taking Insulin Aspart. See all 76 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Doctor's advice | 4 | ||
| Other | 3 | ||
| Did not seem to work | 1 | ||
| Course of treatment ended | 1 | ||
| Change in health plan coverage | 1 |
Adherence
Taking treatment as prescribed
Adherence of Insulin Aspart
Always |
5 | 42% |
|
|---|---|---|---|
Usually |
6 | 50% |
|
Sometimes |
1 | 8% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Insulin Aspart
Very |
2 | 17% |
|
|---|---|---|---|
Somewhat |
1 | 8% |
|
A little |
6 | 50% |
|
Not at all |
3 | 25% |
|
Cost
Paid out of pocket
Cost of Insulin Aspart
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
0 | 0% |
|
< $25 |
8 | 100% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 27, 2012.